Robert A.B. van Waterschoot

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism

Antonius E. van Herwaarden, Els Wagenaar, Cornelia M.M. van der Kruijssen et al. · Journal of Clinical Investigation · 2007 · 234 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

Jurjen S. Lagas, Robert A.B. van Waterschoot, Rolf W. Sparidans et al. · Molecular Cancer Therapeutics · 2010 · 182 citations

Medicine, Pharmacokinetics, Pharmacology +17

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

Jurjen S. Lagas, Robert A.B. van Waterschoot, Vicky A.C.J. van Tilburg et al. · Clinical Cancer Research · 2009 · 173 citations

Medicine, Pharmacokinetics, Pharmacology +16

Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes

Robert A.B. van Waterschoot, Antonius E. van Herwaarden, Jurjen S. Lagas et al. · Molecular Pharmacology · 2007 · 113 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Absence of Both Cytochrome <i>P</i> 450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity

Robert A.B. van Waterschoot, Jurjen S. Lagas, Els Wagenaar et al. · Cancer Research · 2009 · 97 citations

Pharmacy, Pharmacokinetics, Pharmacology +17